---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-034971"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:32:32.199813+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine CSO Jeremy Duffield steps down effective July 15, 2025; retains as consultant through Mar 2026

## Summary
- Jeremy Duffield, M.D., Ph.D., FRCP, resigns as Chief Scientific Officer effective July 15, 2025.
- Company to enter Separation Agreement providing severance per his 2022 employment agreement.
- Duffield retained as consultant from July 15, 2025 through March 31, 2026.
- All outstanding equity awards continue vesting during the Advisory Period.
- No successor named in the filing.

## SEC filing metadata
- accession: 0001628280-25-034971
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025034971/0001628280-25-034971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025034971/prme-20250714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-034971
- JSON: https://secwatch.observer/filing/0001628280-25-034971.json
- Plain text: https://secwatch.observer/filing/0001628280-25-034971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.